Search for dialysis centres here

Find a centre Log in to explore the world's most comprehensive database of dialysis centres for free!

Jobs in dialysis

dialysis.team.logo.small.000 Professional dialysis recruitment 

 

Dialysis industry news

Stories from the dialysis comunity across the globe.
Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care ... - CNNMoney PDF Print

WIXOM, Mich., May 5, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will present at the Bank of America Merrill Lynch 2015 Health Care Conference, being held at the Encore at the Wynn in Las Vegas, Nevada May 12-15, 2015.

About Triferic

Triferic is a unique iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. Triferic is introduced into bicarbonate concentrate, on-site at the dialysis clinic, and subsequently mixed into dialysate. Once in dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. In completed clinical trials, Triferic has demonstrated that it can effectively deliver sufficient iron to the bone marrow and maintain hemoglobin, without increasing iron stores (ferritin). Please visit www.triferic.com for more information.

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell's recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials, Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market.

Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S.

Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and Triferic following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Triferic™ is a trademark of Rockwell Medical, Inc.

CONTACT: Michael Rice, Investor Relations; 646-597-6979
 Top of page

...
 
Post-Transplant Renal Function Decline Predicts Worse Outcomes - Renal and Urology News PDF Print
May 05, 2015 Post-Transplant Renal Function Decline Predicts Worse Outcomes - Renal and Urology News
A 30% decline in eGFR between 1 and 3 years post-transplant is associated with an increased risk of all-cause graft loss and patient death.

PHILADELPHIA—A 30% or greater decline in estimated glomerular filtration rate (eGFR) between years 1 and 3 after kidney transplantation is associated with an increased risk of graft-censored graft failure and patient death, data presented at the 2015 American Transplant Congress suggest.

This magnitude of decline in eGFR potentially may be useful as a surrogate marker in clinical trials looking at the impact of interventions to prevent these outcomes, according to co-investigator Steven J. Chadban, MBBS, PhD, who presented study findings.

Using data from the Australia and New Zealand Dialysis and Transplant Registry, researchers studied 7,949 kidney transplants performed from 1995–2009 who were followed up for a total of 71,845 patient-years. Recipients experienced 1,121 graft losses and 1,192 deaths. Between years 1 and 3 post-transplant, 10% of patients experienced at least a 30% decline in eGFR. This decline was associated with a 6-fold increased risk in death-censored graft loss and a 2.3 times increased risk of patient death compared with stable eGFR.

Greater rates of eGFR decline were associated with progressively higher risks of these outcomes, according to the investigators.

The findings of the new study echo those of a study looking at how eGFR decline affects the subsequent risk of end-stage renal disease (ESRD) and mortality in patients with chronic kidney disease (CKD). The study, published in the Journal of the American Medical Association (2014;311:2518-2531), found that a 30% or greater decline in eGFR from a baseline of less than 60 mL/min/1.73 m2 over 2 years was associated with an increased risk of both outcomes in adjusted analyses.

Dr. Chadban said he and his colleagues concluded that a 30% decline in post-transplant eGFR over 2 years is common and strongly associated with hard outcomes, “and given the fact that it very much mirrors the hard data from CKD, we would propose this as a potential surrogate outcome for future trials in kidney transplantation.”

...
 
Contrast-Induced Nephropathy in Kidney Tx Patients Characterized - Renal and Urology News PDF Print
May 05, 2015 Contrast-Induced Nephropathy in Kidney Tx Patients Characterized - Renal and Urology News
Study reveals a 13% incidence of CIN in allograft recipients undergoing computed tomography or cardiac catheterization with contrast media.

PHILADELPHIA—Contrast-induced nephropathy (CIN) is relatively common in kidney transplant recipients undergoing computed tomography (CT) or cardiac catheterization with contrast media, researchers concluded in a poster presentation at the 2015 American Transplant Congress.

Bassam G. Abu Jawdeh, MD, and colleagues at the University of Cincinnati in Ohio studied 76 contrast exposures (45 CT scans and 31 catheterizations) in 50 kidney transplant recipients (50% male) with a mean age of 53.3 years and mean serum creatinine level of 1.46 mg/dL. The investigators identified CIN—defined as a rise in serum creatinine by more than 0.3 mg/dL or 25% from baseline within 4 days of contrast exposure—in 10 of 76 procedures (13.2%). Results showed that 6 (13.3%) of the 45 CT scans and 4 (12.9%) of the 31 catheterizations resulted in CIN.

Dr. Abu Jawdeh's group also examined risk factors for CIN. In a multivariate model, exposure to N-acetylcysteine (NAC) and a lower hemoglobin level were significantly associated with an increased risk of CIN, but calcineurin inhibitor use was not. Dr. Abu Jawdeh said NAC may have been administered to patients at high risk for CIN, a bias that could explain the increased risk of CIN associated with NAC use.

At the last follow-up, CIN did not affect allograft function and survival, according to the researchers.

“Contrast-induced nephropathy is associated with a significant increase in mortality and morbidity,” Dr. Abu Jawdeh told Renal & Urology News. “Although we often extrapolate what we know about native kidneys to allografts, that might not reflect best practice. Allografts are solitary kidneys that experience significant hemodynamic alterations and kidney recipients are on lifelong immunosuppressive medications. Both of these factors might affect susceptibility to contrast-induced injury. Since data on contrast nephropathy in kidney allografts is limited we decided to proceed with this retrospective study.”

CIN is potentially modifiable if risk factors are identified and preventive measures are taken, said Dr. Abu Jawdeh, an assistant professor in the division of nephrology and hypertension. The 13.3% incidence of CIN identified in the new study is consistent with previous studies looking at native kidneys, he said.

Dr. Abu Jawdeh acknowledged that their study was limited by the small sample size and retrospective design, so the findings should be interpreted cautiously.

 

...
 
Providence building new dialysis center on Novi campus - Hometownlife.com PDF Print
NNO biz Dialysis.jpg

Pictured at the May 1 groundbreaking (l to r) are Victoria Abbott, social worker, DaVita; Carol Rowe, administrative assistant, DaVita; Joe Hurshe, COO, Providence-Providence Park Hospital, Gary Jonna, president, Whitehall Real Estate Interests; David Butera, group facility administrator, DaVita; Peter Karadjoff, president, Providence-Providence Park Hospital, Novi; Dave Stout, Novi mayor pro tem; Derrick Byl, regional operations director, DaVita; Sue Carter-Okab, regional operations director, DaVita; Dr. Fawaz Al-Ejal, medical director, DaVita; and Michael Lynch, project manager, DaVita.(Photo: courtesy)

DaVita Kidney Care on May 1 broke ground on a new dialysis center in partnership with Providence-Providence Park Hospital on its Novi campus.

The dialysis center will consist of two buildings on the hospital campus, one to accommodate in-center dialysis patients and another building for home dialysis therapies, consisting of both peritoneal dialysis and home hemodialysis. Both buildings will be built concurrently and are anticipating an open date in the summer of 2016. The in-center dialysis center will have 20 stations and the home therapies will offer six rooms for home training.

“Partnering with Providence-Providence Park on this dialysis center offers us a chance to provide more convenience for our patients,” said Sue Carter-Okab, a regional operations director at DaVita Kidney Care. “With other outpatient and emergency services readily available on campus, our patients have access to additional on-site resources.”

The campus was built with the intent to create a destination for health in the community, according Peter Karadjoff, president of Providence-Providence Park Hospital.

“DaVita Kidney Care’s presence here will help continue that goal and enhance the healing process for all those visiting,” he said.

In addition to providing space on the hospital campus, the partnership with DaVita Kidney Care will allow practicing nephrologists at the hospital to serve as the center’s medical director. DaVita Kidney Care will provide the staff and care at the dialysis center.

Kidney failure, also known as end stage renal disease (ESRD), is a fatal condition unless a kidney transplant is available or a patient undergoes dialysis, in which a machine filters toxins and fluids from the blood outside the body. In-center dialysis patients are treated four hours a day, three times a week.

An estimated 20 million U.S. adults have chronic kidney disease, which can progress to ESRD. Most are unaware of their condition, as the disease is often symptomless until the kidneys fail. Groups at the highest risk for ESRD include those with diabetes or hypertension as well as older adults, African Americans, Hispanics and Native Americans.

To find out more about DaVita Kidney Care, call 1–800-400-8331 or visit www.DaVita.com.

Read or Share this story: http://www.hometownlife.com/story/news/local/novi/2015/05/05/davita-dialysis-providence-hospital-novi/26875403/

...
 
Chelsea midfielder Ramires celebrates title win on Instagram after returning ... - Daily Mail PDF Print
  • Brazilian star was taken ill before Chelsea's win over Crystal Palace
  • Ramires says he was 'very sick' but it was 'nothing serious'
  • Midfielder will be 'fully recovered in a few weeks' and is with family
  • Ramires 'very pleased with the title' as his side sealed Premier League

By Jonny Singer for MailOnline

Published: 09:40 EST, 4 May 2015 | Updated: 10:41 EST, 4 May 2015

21 View
comments

Chelsea star Ramires has returned home and is recovering well after being rushed to hospital on Sunday with a kidney problem.

The Brazilian midfielder was due to play against Crystal Palace, as Chelsea sealed their Premier League title, but instead had to receive treatment just before kick-off.

But Ramires returned home on Monday and insisted it was 'nothing serious', as he posted a picture of himself celebrating to Instagram. 

Olá pessoal! Como vocês viram, passei muito mal poucos minutos antes do jogo de ontem por causa de uma complicação renal, mas estou sendo tratado desde o ocorrido e já me encontro em casa com meus familiares. Graças a Deus não foi nada grave e em algumas semanas terei minha saúde totalmente restabelecida. Obrigado a todos que me mandaram mensagens de apoio e que demonstraram seu carinho e preocupação de alguma forma. Agradecimento especial a toda junta médica do Chelsea por seu trabalho excepcional. Fiquei triste por não ter participado da festa em campo, mas feliz pela conquista do título, o único que me faltava no futebol inglês. Parabéns Chelsea! Hello guys! As you saw, I was very sick yesterday minutes before the match because of a renal complication, but I'm well and home with my family. Thank God it was nothing serious and I will be fully recovered in a few weeks. Thank you to all that sent me messages and were with me. I would like to thank the Chelsea's medical team for the exceptional job. I was sad not to be part of the party on the pitch, but very pleased with the title, the only English title I had left to concur. Congratulations Chelsea!

A photo posted by Rami7oficial (@rami7oficial) on May 4, 2015 at 7:00am PDT

Ramires was taken ill shortly before Chelsea's Premier League game against Crystal Palace

Ramires was taken ill shortly before Chelsea's Premier League game against Crystal Palace

Share this article

'Hello guys!' wrote the 28-year-old, posing in his home in front of a giant picture of himself. 'As you saw, I was very sick yesterday minutes before the match because of a renal complication, but I'm well and home with my family. 

'Thank God it was nothing serious and I will be fully recovered in a few weeks. Thank you to all that sent me messages and were with me. I would like to thank the Chelsea's medical team for the exceptional job. 

'I was sad not to be part of the party on the pitch, but very pleased with the title, the only English title I had left to concur. Congratulations Chelsea!'

Chelsea midfielder Ramires celebrates title win on Instagram after returning ... - Daily Mail

Ramires has played a key part in the run-in, scoring in their previous game against Leicester City

Chelsea midfielder Ramires celebrates title win on Instagram after returning ... - Daily Mail

Ramires was replaced in the Chelsea starting line-up close to kick-off by Juan Cuadrado (left)

Chelsea midfielder Ramires celebrates title win on Instagram after returning ... - Daily Mail

Chelsea players celebrate at the full-time whistle, but Ramires was absent from the jubilant scenes

...
 
More Articles...
<< Start < Prev 251 252 253 254 255 256 257 258 259 260 Next > End >>

Page 254 of 4210
Share |

Dialysis travel

Dialysis information

Global Dialysis

Copyright © 2025 Global Dialysis. All Rights Reserved.